Basisstatistiken
| LEI | HQD377W2YR662HK5JX27 |
| CIK | 1800 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Abbott Laboratories
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) 100 Abbott Park Road, Abbott Park, IL (Address of Principal Executive Offices) 6006 |
|
| May 27, 2026 |
Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2025 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2025 This report for the year ended December 31, 2025 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as “Abbott,” “we,” “us,” or “our”) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-218 |
|
| April 27, 2026 |
Abbott Laboratories PERFORMANCE Restricted Stock Agreement Exhibit 10.6 Abbott Laboratories PERFORMANCE Restricted Stock Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Award (the “Award”) of « NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admini |
|
| April 27, 2026 |
Abbott Laboratories Performance Restricted Stock Unit Agreement Exhibit 10.7 Abbott Laboratories Performance Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The Award is granted under the Program and is subject to the provisions of the Program, the |
|
| April 27, 2026 |
Abbott Laboratories PERFORMANCE Restricted Stock Agreement Exhibit 10.8 Abbott Laboratories PERFORMANCE Restricted Stock Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Award (the “Award”) of « NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admini |
|
| April 27, 2026 |
ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT Exhibit 10.17 ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Award (the “Award”) of «NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admini |
|
| April 27, 2026 |
ABBOTT LABORATORIES RESTRICTED STOCK AGREEMENT Exhibit 10.20 ABBOTT LABORATORIES RESTRICTED STOCK AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Award (the “Award”) of «NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicab |
|
| April 27, 2026 |
ABBOTT LABORATORIES Non-EMPLOYEE DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.27 ABBOTT LABORATORIES Non-EMPLOYEE DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name», (the “Director”) an Option (the “Option”) to purchase a total of «NoShares12345» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Ma |
|
| April 27, 2026 |
Abbott Laboratories Restricted Stock Unit Agreement Exhibit 10.5 Abbott Laboratories Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The Award is granted under |
|
| April 27, 2026 |
Abbott Laboratories Restricted Stock Unit Agreement Exhibit 10.3 Abbott Laboratories Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on specified Delivery Dates. The Award is granted under |
|
| April 27, 2026 |
Abbott Laboratories Restricted Stock Agreement Exhibit 10.10 Abbott Laboratories Restricted Stock Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Award (the “Award”) of «NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicab |
|
| April 27, 2026 |
Abbott Laboratories Non-employee DIRECTOR Restricted Stock Unit Agreement Exhibit 10.24 Abbott Laboratories Non-employee DIRECTOR Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Director”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The |
|
| April 27, 2026 |
Abbott Laboratories Non-employee DIRECTOR Restricted Stock Unit Agreement Exhibit 10.25 Abbott Laboratories Non-employee DIRECTOR Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Director”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The |
|
| April 27, 2026 |
ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.22 ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the |
|
| April 27, 2026 |
ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.2 ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on specified Delivery Dates. The Award is granted under |
|
| April 27, 2026 |
Abbott Laboratories Performance Restricted Stock Unit Agreement Exhibit 10.9 Abbott Laboratories Performance Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The Award is granted under the Program and is subject to the provisions of the Program, the |
|
| April 27, 2026 |
ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.15 ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The Award is granted unde |
|
| April 27, 2026 |
ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.23 ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the |
|
| April 27, 2026 |
ABBOTT LABORATORIES Non-EMPLOYEE DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.26 ABBOTT LABORATORIES Non-EMPLOYEE DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name», (the “Director”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Val |
|
| April 27, 2026 |
ABBOTT LABORATORIES PERFORMANCE Restricted Stock Agreement Exhibit 10.16 ABBOTT LABORATORIES PERFORMANCE Restricted Stock Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Award (the “Award”) of «NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admini |
|
| April 27, 2026 |
Abbott Laboratories Restricted Stock Agreement Exhibit 10.11 Abbott Laboratories Restricted Stock Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Award (the “Award”) of « NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applica |
|
| April 27, 2026 |
Common Shares, Without Par Value ABT NYSE Texas [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2026 |
ABBOTT LABORATORIES RESTRICTED STOCK AGREEMENT Exhibit 10.21 ABBOTT LABORATORIES RESTRICTED STOCK AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Award (the “Award”) of «NoShares12345» Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program administrative rules, applicab |
|
| April 27, 2026 |
ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.18 ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The Award is granted under the Program and is subject to the provisions of the Program, th |
|
| April 27, 2026 |
ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.14 ABBOTT LABORATORIES RESTRICTED STOCK UNIT AGREEMENT On «GrantDay» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The Award is granted under |
|
| April 27, 2026 |
Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 24, 2026 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may have such other office |
|
| April 27, 2026 |
ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT Exhibit 10.19 ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the “Units”). The Award is granted under the Program and is subject to the provisions of the Program, th |
|
| April 27, 2026 |
Abbott Laboratories Restricted Stock Unit Agreement Exhibit 10.4 Abbott Laboratories Restricted Stock Unit Agreement On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) a Restricted Stock Unit Award (the “Award”) of « NoShares12345» restricted stock units (the “Units”) representing the right to receive an equal number of Shares on a specified Delivery Date. The Award is granted unde |
|
| April 27, 2026 |
ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.12 ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NoShares12345» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Share |
|
| April 27, 2026 |
ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.13 ABBOTT LABORATORIES NON-QUALIFIED STOCK OPTION AGREEMENT On «GrantDate» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the “Employee”) an Option (the “Option”) to purchase a total of «NQSOs» Shares, at the price of $«OptionPrice» per Share (the “Exercise Price”), such price being not less than 100% of the Fair Market Value of the Shares on the |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 24, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 ABBOTT LABORATORIES Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, Without Par Value Other 140,000,000 $ 91. |
|
| April 17, 2026 |
Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATION CASE NO: 1:22-cv-5513 Hon. Sunil R. Harjani Hon. Laura K. McNally -x NOTICE OF PROPOSED SETTLEMENT OF CONSOLIDATED DERIVATIVE ACTION, FINAL SETTLEMENT HEARING, AND RIGHT TO APPEAR TO: ALL CURRENT HOLDERS OF ABBOTT LABO |
|
| April 17, 2026 |
Common Shares, Without Par Value ABT NYSE Texas [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2026 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences –First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent –Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market –Abbott projects full-year 2026 comparable sales g |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2026 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number |
|
| March 23, 2026 |
Exhibit 99.1 News Release Abbott completes acquisition of Exact Sciences · Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments · Advances Abbott’s mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026— Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, esta |
|
| March 23, 2026 |
Common Shares, Without Par Value ABT NYSE Texas [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 23, 2026 |
As filed with the Securities and Exchange Commission on March 23, 2026 As filed with the Securities and Exchange Commission on March 23, 2026 Registration No. |
|
| March 23, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 ABBOTT LABORATORIES Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Shares, without par value Other 1,476,916 $ 106. |
|
| March 13, 2026 |
Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6400 U.S.A. On the Cover: STRAN SMITH Childress, Texas, USA Amplatzer PFO Occluder When Stran, a rancher and rodeo world champion, had a stroke at 32 caused by a patent foramen ovale (PFO) — an opening between the right and left sides of the upper chambers of the heart — he received an Amplatzer PFO occluder. Today, he's back in |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 13, 2026 |
ANNUAL REPORT TO SECURITY HOLDERS 2025 Annual Report1 Letter to shareholders 5 Durable by design 6 Building on breadth 8 Creating the future 10 Driven by people 12 Biowearables 14 Neuromodulation 16 Cardiac Rhythm Management 18 Electrophysiology 20 Structural Heart 22 Vascular 24 Heart Failure Management 26 Medicines 28 Laboratory Diagnostics 30 Rapid and Molecular Diagnostics 32 Nutrition 34 Making a difference 36 Financial Report 2025 Annual Report When Stran, a rancher and rodeo world champion, had a stroke at 32 caused by a patent foramen ovale (PFO) — an opening between the right and left sides of the upper chambers of the heart — he received an Amplatzer PFO occluder. |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 9, 2026 |
ABBOTT LABORATORIES OFFICERS’ CERTIFICATE PURSUANT TO SECTIONS 3.1 AND 3.3 OF THE INDENTURE Exhibit 4.2 Execution Version ABBOTT LABORATORIES OFFICERS’ CERTIFICATE PURSUANT TO SECTIONS 3.1 AND 3.3 OF THE INDENTURE The undersigned, Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer of Abbott Laboratories (“Abbott” or the “Company”), and James R. Wenner, Vice President, Treasurer of the Company, hereby certify, pursuant to (i) Sections 3.1 and 3.3 of the Inde |
|
| March 9, 2026 |
Common Shares, Without Par Value ABT NYSE Texas [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2026 |
Common Shares, Without Par Value ABT NYSE Texas [Member] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2026 |
Exhibit 1.1 Pricing Agreement Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 and Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 and BofA Securities, Inc. One Bryant Park New York, New York 10036 and J.P. Morgan Securities LLC 270 Park Avenue New York, New York 10017 As Representatives of the several Underwriters named in Schedule I hereto February 23, 2026 Ladie |
|
| February 25, 2026 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-293636 Prospectus Supplement (To Prospectus dated February 23, 2026) $20,000,000,000 Abbott Laboratories $1,000,000,000 Floating Rate Notes due 2029 $2,250,000,000 3.700% Notes due 2029 $2,500,000,000 4.000% Notes due 2031 $2,750,000,000 4.300% Notes due 2033 $3,750,000,000 4.650% Notes due 2036 $2,000,000,000 4.750% Notes d |
|
| February 25, 2026 |
Calculation of Filing Fee Tables S-3 ABBOTT LABORATORIES Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Floating Rate Notes due 2029 457(r) $ 1,000,000,000. |
|
| February 24, 2026 |
FINAL TERM SHEET Floating Rate Notes due 2029 Filed Pursuant to Rule 433 Dated February 23, 2026 Registration Statement No. 333-293636 FINAL TERM SHEET Floating Rate Notes due 2029 Issuer: Abbott Laboratories Principal Amount: $1,000,000,000 Interest: The Floating Rate Notes will bear interest at a floating rate equal to a benchmark rate, which will initially be Compounded SOFR (as defined in the Prospectus Supplement under “Description of No |
|
| February 23, 2026 |
Subject to Completion Dated February 23, 2026 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 23, 2026 |
Calculation of Filing Fee Tables S-3 ABBOTT LABORATORIES Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Debt Securities 457(r) 0. |
|
| February 23, 2026 |
Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Emp |
|
| February 23, 2026 |
As filed with the Securities and Exchange Commission on February 23, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 23, 2026 Registration No. |
|
| February 20, 2026 |
Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, December 12, 2025 as amended and restated, effective April 24, 2026 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may have such other off |
|
| February 20, 2026 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 20, 2026 |
SUBSIDIARIES OF ABBOTT LABORATORIES Exhibit 21 SUBSIDIARIES OF ABBOTT LABORATORIES The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2026. |
|
| February 20, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 1-2189Abbott Laboratories An Illinois Co |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 22, 2026 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook –Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent –Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent –Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% |
|
| December 12, 2025 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 12, 2025 |
Exhibit 99.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 12, 2025 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may have such other of |
|
| November 21, 2025 |
Notice of Blackout Period to Directors and Executive Officers of Abbott Laboratories Exhibit 99.1 Notice of Blackout Period to Directors and Executive Officers of Abbott Laboratories This notice explains certain restrictions on your investments in securities of Abbott Laboratories (“Abbott”) during an upcoming retirement plan blackout period. As a director or executive officer of Abbott, you are subject to restrictions under Section 306(a) of the Sarbanes-Oxley Act of 2002 (“Sarba |
|
| November 21, 2025 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 20, 2025 |
Acquisition of Exact Sciences 20 | November | 2025 Exhibit 99.2 Acquisition of Exact Sciences 20 | November | 2025 2 Information Related to This Communication 5 Forward - Looking Statements This communication contains forward - looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott Laboratories (“Abbott”). Forward - looking statements involve substantial risks and uncertainties that could cause actual re |
|
| November 20, 2025 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2025 (November 19, 2025) Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in its charter) Illinois 1-2189 36-0698440 (State or |
|
| November 20, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG ABBOTT LABORATORIES, BADGER MERGER SUB I, INC. AND EXACT SCIENCES CORPORATION DATED AS OF NOVEMBER 19, 2025 TABLE OF CONTENTS Page Article I DEFINED TERMS - 2 - Section 1.1 Certain Defined Terms - 2 - Section 1.2 Additional Defined Terms - 17 - Section 1.3 Interpretation - 19 - Article II THE MERGER AND CERTAIN RELATED MATTERS - 20 - Section 2. |
|
| November 20, 2025 |
Exhibit 99.1 Press Release Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments · Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments · Acquisition will uniquely pos |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1 |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 15, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 15, 2025 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance –Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 –Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30 –Reported operating margin of 18.1 percent of sales; adjusted operating margin of |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 |
|
| July 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 17, 2025 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Second-Quarter 2025 Results –Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 –Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 –Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 ba |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION |
|
| May 29, 2025 |
Conflict Minerals Report for the Year Ended December 31, 2024 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2024 This report for the year ended December 31, 2024 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as “Abbott,” “we,” “us,” or “our”) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) 100 Abbott Park Road, Abbott Park, IL 60064-6400 (Address of Principal Executive Of |
|
| May 1, 2025 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-218 |
|
| April 30, 2025 |
Abbott Laboratories Non-Employee Directors' Fee Plan, as amended and restated. Exhibit 10.1 As Amended and Restated effective May 1, 2025 ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN SECTION 1. PURPOSE ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN - referred to below as the “Plan” - has been established by ABBOTT LABORATORIES - referred to below as the “Company” - to attract and retain as members of its Board of Directors persons who are not full-time employee |
|
| April 28, 2025 |
Submission of Matters to a Vote of Security Holders Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2025 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 9.1 News Release Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance –First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 –First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 –Reported gross margin of 52.8 percent of sales; adjusted gross margin o |
|
| April 16, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2025 |
ANNUAL REPORT TO SECURITY HOLDERS Abbott 2 0 2 4 ANNU AL REPORTFRONT COVER: Her mother knew early in her life that something in Trinity’s body wasn’t working right. |
|
| March 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 6, 2025 |
144 0001530893 XXXXXXXX LIVE 0000001800 ABBOTT LABORATORIES 001-02189 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064 (224) 667-6100 Lisa D. |
|
| February 21, 2025 |
Abbott Laboratories Deferred Compensation & Restoration Plan, as amended and restated.** Exhibit 10.2 ABBOTT LABORATORIES DEFERRED COMPENSATION & RESTORATION PLAN (Amended and Restated Effective June 1, 2024) Table of Contents Page ARTICLE I Introduction Section 1.1 Purpose 1 Section 1.2 ERISA 1 Section 1.3 Employers 1 Section 1.4 Grandfathered Amounts 1 Section 1.5 Effective Date 1 ARTICLE II Definitions 1 Section 2.1 Account 1 Section 2.2 ARP. 2 Section 2.3 Base Compensation 2 Secti |
|
| February 21, 2025 |
Subsidiaries of Abbott Laboratories. Exhibit 21 SUBSIDIARIES OF ABBOTT LABORATORIES The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2025. |
|
| February 21, 2025 |
Exhibit 10.47 [Date] To: [Executive] Re: Notice of CIC Extension Abbott’s Board of Directors recently extended your Change in Control (CIC) Agreement. Its term now continues through December 31, 2026. The CIC Agreement provides you with financial, health and welfare benefits in the event of a Change in Control. No action is required on your part to continue participation in the CIC agreement. You |
|
| February 21, 2025 |
Abbott Laboratories 401(k) Supplemental Plan, as amended and restated.** Exhibit 10.3 Amended and Restated effective June 1, 2024 ABBOTT LABORATORIES 401(k) SUPPLEMENTAL PLAN SECTION 1 INTRODUCTION 1-1. PURPOSE. This Abbott Laboratories 401(k) Supplemental Plan (the “Plan”) is being established by Abbott Laboratories (“Abbott”) to provide eligible management employees of Abbott an opportunity to accumulate capital for their retirement or other termination of employment |
|
| February 21, 2025 |
Abbott Laboratories Insider Trading Policy. Exhibit 19 ABBOTT LABORATORIES INSIDER TRADING POLICY 1.0 Overview The securities laws of the United States prohibit a person from trading in a company’s publicly-traded securities while that person is in possession of material non-public information regarding the company. Persons who trade while in possession of material non-public information can be imprisoned, subjected to criminal fines, and a |
|
| February 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 1-2189 Abbott Laboratories An Illinois C |
|
| January 22, 2025 |
Exhibit 99.1 9.1 News Release Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook –Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion –Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 –Full-year 2024 reported sales increased 4.6 percent; organic sales grow |
|
| January 22, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 15, 2024 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2024 |
144 0001565892 XXXXXXXX LIVE 0000001800 ABBOTT LABORATORIES 001-02189 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-3500 2246676100 Funck, Jr. |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1 |
|
| October 16, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 16, 2024 |
Exhibit 99.1 1 News Release Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range –Sales of $10.6 billion driven by strong underlying base business performance –Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices –Continues to strengthen portfolio with steady c |
|
| September 12, 2024 |
144 0001612571 XXXXXXXX LIVE 0000001800 ABBOTT LABORATORIES 001-02189 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064 (224) 667-6100 Robert B. |
|
| September 4, 2024 |
144 0001565892 XXXXXXXX LIVE 0000001800 ABBOTT LABORATORIES 001-02189 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-3500 2246676100 Funck, Jr. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 |
|
| July 18, 2024 |
Exhibit 99.1 9.1 News Release Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance –Sales of $10.4 billion driven by strong underlying base business performance –Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices –Continues to strengthen portfolio with new product approvals ABBOT |
|
| July 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 18, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) 100 Abbott Park Road, Abbott Park, IL (Address of Principal Executive Offices) 6006 |
|
| May 30, 2024 |
Conflict Minerals Report for the Year Ended December 31, 2023 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2023 This report for the year ended December 31, 2023 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as “Abbott,” “we,” “us,” or “our”) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-218 |
|
| May 1, 2024 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2024 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number |
|
| April 17, 2024 |
Exhibit 99.1 News Release Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges –Sales of $10.0 billion driven by strong underlying base business performance –Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year –Organic sales growth for underlying base business of 10.8 |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 15, 2024 |
N OT I C E OF AN N UAL M EE T I N G OF SH AR EH OL D ER S AN D P ROX Y S TATE M E NT 2024Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6400 U. |
|
| March 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 15, 2024 |
ANNUAL REPORT TO SECURITY HOLDERS 2023 ANNUAL REPORTTABLE OF CONTENTS 1 Letter to Shareholders 5 Abbott 2023 6 From Data to Decisions 8 Laboratory Diagnostics 10 Rapid Diagnostics 12 Vascular 14 Electrophysiology 16 From Insight to Innovation 18 Structural Heart 20 Neuromodulation 22 Heart Failure Management 24 Cardiac Rhythm Management 26 From Engagement to Empowerment 28 Medicines 30 Nutrition 32 Diabetes Care 34 The Future in Fast Forward 36 Financial Report Throughout our long history, we have continually reinvented Abbott to meet the needs of every age and stage of a person’s life, innovating to create leading-edge technologies that empower individuals to take ever-increasing control over their own health. |
|
| February 16, 2024 |
Abbott Laboratories Dodd-Frank Clawback Policy Exhibit 97 ABBOTT LABORATORIES DODD-FRANK CLAWBACK POLICY Abbott Laboratories (collectively with its affiliates, the “Company”) has adopted this Dodd-Frank Clawback Policy (the “Policy”), effective as of October 1, 2023 (the “Effective Date”). |
|
| February 16, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 1-2189Abbott Laboratories An Illinois Co |
|
| February 16, 2024 |
Subsidiaries of Abbott Laboratories. Exhibit 21 SUBSIDIARIES OF ABBOTT LABORATORIES The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2024. |
|
| February 16, 2024 |
1998 Abbott Laboratories Performance Incentive Plan, as amended and restated Exhibit 10.6 As Amended and Restated, effective October 1, 2023 1998 ABBOTT LABORATORIES PERFORMANCE INCENTIVE PLAN SECTION 1. ESTABLISHMENT AND PURPOSES 1.1ESTABLISHMENT OF THE PLAN. Abbott Laboratories ("Abbott") established the "1998 Abbott Laboratories Performance Incentive Plan" (the "Plan"), as set forth in this document. The Plan became effective as of January 1, 1998 (the "Effective Date") |
|
| February 16, 2024 |
Abbott Laboratories 2017 Incentive Stock Program, as amended and restated Exhibit 10.9 As Amended and Restated, effective October 1, 2023 Abbott Laboratories 2017 Incentive Stock Program 1. PURPOSE. The purpose of the Abbott Laboratories 2017 Incentive Stock Program is to attract and retain outstanding directors, officers and other employees of Abbott Laboratories and its Subsidiaries, and to furnish incentives to such persons by providing opportunities to acquire commo |
|
| February 16, 2024 |
Exhibit 10.65 Execution Version U.S. $5,000,000,000 FIVE YEAR CREDIT AGREEMENT Dated as of January 29, 2024 among ABBOTT LABORATORIES, as Borrower, and VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent, and BARCLAYS BANK PLC BANK OF AMERICA, N.A. and MORGAN STANLEY SENIOR FUNDING, INC. as Syndication Agents JPMORGAN CHASE BANK, N.A. BARCLAYS BANK PL |
|
| February 16, 2024 |
1986 Abbott Laboratories Management Incentive Plan, as amended and restated Exhibit 10.5 As Amended and Restated effective October 1, 2023 1986 ABBOTT LABORATORIES MANAGEMENT INCENTIVE PLAN SECTION 1 INTRODUCTION 1.1 BACKGROUND AND PURPOSES. This 1986 ABBOTT LABORATORIES MANAGEMENT INCENTIVE PLAN (the “Plan”) is a successor Plan to the 1961, 1971 and 1981 Management Incentive Plans (the “Predecessor Plans”). This Plan is being established by ABBOTT LABORATORIES (“Abbott”) |
|
| February 13, 2024 |
ABT / Abbott Laboratories / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0163-abbottlaboratories.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Abbott Laboratories Title of Class of Securities: Common Stock CUSIP Number: 002824100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desig |
|
| January 29, 2024 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 26, 2024 |
ABT / Abbott Laboratories / BlackRock Inc. Passive Investment SC 13G/A 1 us0028241000012624.txt us0028241000012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) ABBOTT LABORATORIES - (Name of Issuer) Common Stock - (Title of Class of Securities) 002824100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| January 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 24, 2024 |
Exhibit 99.1 9.1 News Release Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook –Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent –Full-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underly |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1 |
|
| October 18, 2023 |
Exhibit 99.1 9 9.1 News Release Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range –Sales of $10.1 billion driven by strong underlying base business performance –Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –Organic sales growth for underlying base business of 13.8 percent, reflects do |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 18, 2023 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 1, 2023 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 |
|
| August 3, 2023 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this “Agreement”), dated as of May 12, 2023, is among ABBOTT LABORATORIES (the “Borrower”), the banks, financial institutions and other institutional lenders parties to the Credit Agreement referred to below (collectively, the “Lenders”) and JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Ag |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 20, 2023 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 20, 2023 |
Exhibit 99.1 9.1 News Release Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business –Sales of $10.0 billion driven by strong underlying base business performance –Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –Organic sales growth for underlying base business of 11.5 percent, led by Medical |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION |
|
| June 12, 2023 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 9, 2023 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction (Commission File No.) (I.R.S. Employer of Incorporation) Identification Number) 100 Abbott Park Road, Abbott Park, IL 60064-6400 (Address of Principal Executive Of |
|
| May 31, 2023 |
Conflict Minerals Report for the Year Ended December 31, 2022 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2022 This report for the year ended December 31, 2022 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as “Abbott,” “we,” “us,” or “our”) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| May 4, 2023 |
non-employedirectorsfeep Exhibit 10.1 As Amended and Restated effective May 1, 2023 ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN SECTION 1. PURPOSE ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN - referred to below as the “Plan” - has been established by ABBOTT LABORATORIES - referred to below as the “Company” - to attract and retain as members of its Board of Directors persons who a |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-218 |
|
| May 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Abbott Laboratories (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| May 3, 2023 |
Statement of Eligibility of U.S. Bank Trust Company, National Association on Form T-1. Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ¨ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| May 3, 2023 |
As filed with the Securities and Exchange Commission on May 3, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 3, 2023 Registration No. |
|
| May 2, 2023 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 19, 2023 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number |
|
| April 19, 2023 |
Exhibit 99.19.1 News Release Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business –Sales of $9.7 billion driven by strong underlying base business performance –Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –Organic sales growth for underlying base business of 10.0 percent, led by Medical Dev |
|
| April 10, 2023 |
Name of Registrant: Abbott Laboratories NAME OF PERSON RELYING ON EXEMPTION: Shareholder Association for Research & Education (SHARE) ADDRESS OF PERSON RELYING ON EXEMPTION: Suite 440, 789 West Pender Street Vancouver, BC V6C 1H2 Subject: Item #8 – “Shareholder Proposal on Incentive Compensation” Annual Meeting: April 28, 2023 Contact: Kevin Thomas, Chief Executive Officer, SHARE, kthomas@share. |
|
| April 5, 2023 |
United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Abbott Laboratories NAME OF PERSONS RELYING ON EXEMPTION: Province of Saint Joseph of the Capuchin Order ADDRESS OF PERSON RELYING ON EXEMPTION: 930 West State Street, Milwaukee WI 53233 WRITTEN MATERIALS: The attached written materials are submitted pursuant to Rule 14a-6(g)(1) (the “Rule”) promulgated under the Securities Exchange Act of 1934. |
|
| March 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 17, 2023 |
N OT I C E OF AN N UAL M EE T I N G OF SH AR EH OL D ER S AN D P R OX Y S TATE M E NT 2023Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6400 U. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 17, 2023 |
ANNUAL REPORT TO SECURITY HOLDERS 2 0 2 2 ANNU AL REPORTDuring a routine physical, Jay King’s doctor discovered that Jay was suffering from atrial fibrillation. |
|
| February 17, 2023 |
Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 28, 2023 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may have such other office |
|
| February 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 1-2189Abbott Laboratories An Illinois Co |
|
| February 17, 2023 |
Subsidiaries of Abbott Laboratories. abt-20221231x10kexx21 Exhibit 21 Name Jurisdiction Abbott Biologicals, LLC Delaware Abbott Cardiovascular Inc. |
|
| February 17, 2023 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 17, 2023 |
abt-20221231x10kexx1059 Exhibit 10.59 [Date] To: [Executive] Re: CIC Notification of Extension Abbott’s Board of Directors recently extended your Change in Control (CIC) agreement. Its term now continues through December 31, 2024. The CIC agreement provides you with financial, health and welfare benefits in the event of a Change in Control. No action is required on your part to continue participat |
|
| February 9, 2023 |
ABT / Abbott Laboratories / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Abbott Laboratories Title of Class of Securities: Common Stock CUSIP Number: 002824100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 6, 2023 |
ABT / Abbott Laboratories / BlackRock Inc. Passive Investment us0028241000020623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) ABBOTT LABORATORIES - (Name of Issuer) Common Stock - (Title of Class of Securities) 002824100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 25, 2023 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 25, 2023 |
Exhibit 99.1 News Release Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook –Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion –Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent –Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 –Continues to strengthen portfolio with steady cadence |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 ABBOTT LABORATORIES (Exact name of registrant as specified in its charter) Illinois (State or other jurisdiction of incorporation) 1-2189 36-0698440 (Commission File |
|
| December 9, 2022 |
Amended and Restated By-laws of Abbott Laboratories, effective as of December 9, 2022 Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 9, 2022 Article I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corporation may |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1 |
|
| October 21, 2022 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 19, 2022 |
Exhibit 99.1 News Release Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance ?Worldwide sales of $10.4 billion in the third quarter ?Raises full-year earnings-per-share guidance ?Continues to strengthen portfolio with new product approvals and launches ABBOTT PARK, Ill., Oct. 19, 2022 ? Abbott today announced financial results for the third quarter ended Sept. 30, 2022. ?T |
|
| October 19, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 19, 2022 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 15, 2022 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 15, 2022 |
By-Laws of Abbott Laboratories, as amended and restated effective September 15, 2022. Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective September 15, 2022 BY-LAWS OF ABBOTT LABORATORIES ARTICLE I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Cor |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 |
|
| July 20, 2022 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance - Sales growth of 10.1 percent; organic sales growth of 14.3 percent - GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent - Global COVID-19 testing-related sales of $2.3 billion in the second quarter - Continues to strengthen portfolio with new product approvals |
|
| July 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 27, 2022 |
11-K 1 tm2219370d111k.htm FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TR |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction (Commission File No.) (I.R.S. Employer of Incorporation) Identification Number) 100 Abbott Park Road, Abbott Park, IL 60064-6400 (Address of Principal Executive Of |
|
| May 27, 2022 |
Conflict Minerals Report for the Year Ended December 31, 2021 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2021 This report for the year ended December 31, 2021 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as ?Abbott,? ?we,? ?us,? or ?our?) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 2, 2022 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2022 |
Exhibit 99.1 News Release Abbott Reports First-Quarter 2022 Results - Sales growth of 13.8 percent; organic sales growth of 17.5 percent - Global COVID-19 testing-related sales of $3.3 billion in the first quarter - Excluding COVID-19 testing-related sales, first-quarter reported sales growth of 3.9 percent and organic sales growth of 7.7 percent - GAAP diluted EPS growth of 37.0 percent; adjusted |
|
| April 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 25, 2022 |
Abbott Laboratories (ABT) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 ABT Shareholder since 2018 Please Vote For Proposal 4 ? Special Shareholder Meeting Improvement In response to this proposal it is important for Abbott Laboratories management to clarify whether only shareholders of record are now qualified to contribute to the 20% of all shares outstanding needed to call for a special shareholder meeting. |
|
| March 24, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Abbott Laboratories Name of persons relying on exemption: The Shareholder Commons, Inc. Address of persons relying on exem |
|
| March 21, 2022 |
PX14A6G 1 g321223px14a6g.htm March 24, 2022 ABBOTT LABORATORIES Please Support Proposal for Report on Lobbying Spending and Governance To Abbott Laboratories Shareholders: The Unitarian Universalist Common Endowment Fund LLC is urging shareholders to vote FOR Item 7 at the Abbott Laboratories (“Abbott”) shareholder meeting on April 29, 2022. This notice of exempt solicitation is being provided on |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 18, 2022 |
DEF 14A 1 abt3910011-def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidenti |
|
| March 18, 2022 | ||
| February 22, 2022 |
By-Laws of Abbott Laboratories, as amended and restated, effective April 29, 2022. Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 29, 2022 BY-LAWS OF ABBOTT LABORATORIES ARTICLE I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corpora |
|
| February 22, 2022 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 18, 2022 |
Subsidiaries of Abbott Laboratories. Exhibit 21 ? SUBSIDIARIES OF ABBOTT LABORATORIES The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2022. |
|
| February 18, 2022 |
Exhibit 4.36 DESCRIPTION OF THE REGISTRANT?S COMMON SHARES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a description of the principal terms of Abbott Laboratories? common shares. The following description is not meant to be complete and is qualified by reference to Abbott?s Restated Articles of Incorporation and By-Laws, each of which is incorporated |
|
| February 18, 2022 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ? ? (MARK ONE) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2021 Commission file number 1-2189 ? Abbott Laboratories ? ? An Illinois |
|
| February 11, 2022 |
United States securities and exchange commission logo February 11, 2022 Robert B. Ford President and Chief Executive Officer ABBOTT LABORATORIES 100 Abbott Park Road Abbott Park, Illinois 60064-6400 Re: ABBOTT LABORATORIES Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 19, 2021 File No. 001-02189 Dear Mr. Ford: We have completed our review of your filing. We remind you that t |
|
| February 9, 2022 |
ABT / Abbott Laboratories / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0137-abbottlaboratories.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Abbott Laboratories Title of Class of Securities: Common Stock CUSIP Number: 002824100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to design |
|
| February 4, 2022 |
CORRESP 1 filename1.htm February 4, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attention: Margaret Schwartz Christopher Edwards RE: File No. 001-02189 Dear Ms. Schwartz and Mr. Edwards: In reply to your letter of December 23, 2021, we supplement our response to Comment 2 submitted on January 3 |
|
| February 1, 2022 |
ABT / Abbott Laboratories / BlackRock Inc. Passive Investment us0028241000013122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) ABBOTT LABORATORIES - (Name of Issuer) Common Stock - (Title of Class of Securities) 002824100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 31, 2022 |
CORRESP 1 filename1.htm January 31, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attention: Margaret Schwartz Christopher Edwards RE: File No. 001-02189 Dear Ms. Schwartz and Mr. Edwards: In reply to your letter of December 23, 2021, we have enclosed our response in the attachment hereto. Very t |
|
| January 26, 2022 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast - Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent - Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter - Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent - Full-year 20 |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 23, 2021 |
United States securities and exchange commission logo December 23, 2021 Robert B. Ford President and Chief Executive Officer ABBOTT LABORATORIES 100 Abbott Park Road Abbott Park, Illinois 60064-6400 Re: ABBOTT LABORATORIES Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 19, 2021 File No. 001-02189 Dear Mr. Ford: We have reviewed your October 5, 2021 response to our comment let |
|
| December 13, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 10, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 10, 2021 |
Exhibit 99.1 Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman ABBOTT PARK, Ill., Dec. 10, 2021 ? Abbott announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board, effective today. Miles D. White, executive chairman and former CEO, will step down from the Abbott Board effective today and will re |
|
| December 10, 2021 |
By-Laws of Abbott Laboratories, as amended and restated effective December 10, 2021. Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 10, 2021 BY-LAWS OF ABBOTT LABORATORIES ARTICLE I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corp |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 20, 2021 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance - Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent - GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent - Global COVID-19 testing-related sales were $1.9 billion in the thir |
|
| October 5, 2021 |
CORRESP 1 filename1.htm October 5, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attention: Margaret Schwartz Christopher Edwards RE: File No. 001-02189 Dear Ms. Schwartz and Mr. Edwards: In reply to your letter of September 21, 2021, we have enclosed our response in the attachment hereto. Very t |
|
| September 21, 2021 |
United States securities and exchange commission logo September 21, 2021 Robert B. |
|
| September 1, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 1, 2021 |
By-Laws of Abbott Laboratories, as amended and restated effective August 30, 2021. Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective August 30, 2021 BY-LAWS OF ABBOTT LABORATORIES ARTICLE I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corpor |
|
| August 4, 2021 |
F1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents F1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 22, 2021 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports Second-Quarter 2021 Results - Sales growth of 39.5 percent; organic sales growth of 35.0 percent - GAAP diluted EPS from continuing operations growth of 120.0 percent; adjusted diluted EPS growth of 105.3 percent - Second-quarter sales, excluding COVID-19 testing-related sales, grew 12.3 percent on a reported basis and 11.3 percent on an organic basis compa |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION |
|
| June 3, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 3, 2021 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Issues Updated 2021 Outlook ? Updated outlook reflects lower recent and projected demand for COVID-19 tests ? Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis ? Abbott's base business, excluding COVID-19 testing-related sales, continues to achieve strong growth ? R&D pipeline continues to be highly productive, |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Abbott Laboratories (Exact Name of Registrant as Specified in Charter) Illinois 1-2189 36-0698440 (State or Other Jurisdiction (Commission File No.) (I.R.S. Employer of Incorporation) Identification Number) 100 Abbott Park Road, Abbott Park, IL 60064-6400 (Address of Principal Executive Of |
|
| May 28, 2021 |
Conflict Minerals Report for the Year Ended December 31, 2020 Exhibit 1.01 Abbott Laboratories Conflict Minerals Report For the Year Ended December 31, 2020 This report for the year ended December 31, 2020 has been prepared by Abbott Laboratories and its consolidated subsidiaries, as context requires (herein referred to as ?Abbott,? ?we,? ?us,? or ?our?) and is submitted in accordance with Rule 13p-1 of the Securities Exchange Act of 1934 (the Rule), and reg |
|
| May 5, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 26, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2021 |
Exhibit 3.1 A B B O T T L A B O R A T O R I E S AMENDED AND RESTATED ARTICLES OF INCORPORATION Restated Article R-I 1. The name of the corporation is: Abbott Laboratories. 2. The corporation was incorporated March 6, 1900 under the name: The Abbott Alkaloidal Company. 3. Subsequent corporate names and the dates of their adoption are: Name Date Adopted Abbott Laboratories May 29, 1915 Restated Arti |
|
| April 20, 2021 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott Reports First-Quarter 2021 Results - Sales growth of 35.3 percent; organic sales growth of 32.9 percent - GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent - All four major businesses achieved strong sales growth in the quarter - Projected full-year EPS remains unchanged; reflects growth of more than 3 |
|
| April 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 17, 2021 |
2150 Kittredge St. Suite 450 www.asyousow.org Berkeley, CA 94704 BUILDING A SAFE, JUST, AND SUSTAINABLE WORLD SINCE 1992 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of the Registrant: Abbott Laboratories (ABT) Name of persons relying on exemption: As You Sow Address of persons relying on exemption: 2150 Kittredge St. Suite 450, Berkeley, CA 94704 Written materials are submitted pur |
|
| March 12, 2021 |
COURTESY PDF OF PROXY STATEMENT NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND PROXY STATEMENT 2021Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-6400 U. |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 12, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 19, 2021 |
Exhibit 10.74 ? ABBOTT OVERSEAS MANAGERS PENSION PLAN ? ARTICLE 1 INTRODUCTION ? 1.1 Purpose. The Abbott Overseas Managers Pension Plan provides retirement income to Participants, none of whom are United States citizens (other than designated Overseas Managers who are United States citizens and for whom the Company or an Affiliate provides tax equalization based on Puerto Rico tax law) or Resident |
|
| February 19, 2021 |
EX-10.75 14 abt-20201231xex10d75.htm EXHIBIT 10.75 Exhibit 10.75 Execution Version U.S. $5,000,000,000 FIVE YEAR CREDIT AGREEMENT Dated as of November 12, 2020 among ABBOTT LABORATORIES, as Borrower, and VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and JPMORGAN CHASE BANK, N.A., as Administrative Agent, and BARCLAYS BANK PLC BANK OF AMERICA, N.A. and MORGAN STANLEY SENIOR FUNDING, INC. as Syndicati |
|
| February 19, 2021 |
Exhibit 10.63 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Award (the ?Award?) of ?NoShares12345? Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admi |
|
| February 19, 2021 |
Exhibit 10.62 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Award (the ?Award?) of ?NoShares12345? Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program admi |
|
| February 19, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ? ? (MARK ONE) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2020 Commission file number 1-2189 ? Abbott Laboratories ? ? An Illinois C |
|
| February 19, 2021 |
? Exhibit 10.56 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Unit Award (the ?Award?) of ?NoShares12345? restricted stock units (the ?Units?). The Award is granted under the Program and is subject to the provisions of the Program |
|
| February 19, 2021 |
? Exhibit 10.58 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Award (the ?Award?) of ? NoShares12345? Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program a |
|
| February 19, 2021 |
Exhibit 10.68 TIME SHARING AGREEMENT This Time Sharing Agreement ("Agreement") is dated as of , 2020 by and between Abbott Laboratories Inc. ("Company") and ("Executive"). RECITALS WHEREAS, Company owns or rightfully possesses and operates the aircraft set forth in Exhibit A attached hereto (individually and collectively, as the context requires, the "Aircraft"); and WHEREAS, Company employs a ful |
|
| February 19, 2021 |
Exhibit 10.61 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Unit Award (the ?Award?) of ?NoShares12345? restricted stock units (the ?Units?). The Award is granted under the Program and is subject to the provisions of the Program, |
|
| February 19, 2021 |
Exhibit 10.60 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Unit Award (the ?Award?) of ?NoShares12345? restricted stock units (the ?Units?). The Award is granted under the Program and is subject to the provisions of the Program, |
|
| February 19, 2021 |
Exhibit 10.2 ? ABBOTT LABORATORIES ? DEFERRED COMPENSATION PLAN ? ARTICLE I ? Introduction ? Section 1.1 Purpose. The Plan is designed to assist the Employers in attracting and retaining key employees by providing those employees with the opportunity to defer the receipt of a portion of their compensation and to have that deferred compensation treated as if it were invested pending its distributio |
|
| February 19, 2021 |
Exhibit 10.59 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Award (the ?Award?) of ? NoShares12345? Shares. The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the Program adm |
|
| February 19, 2021 |
Subsidiaries of Abbott Laboratories. Exhibit 21 ? SUBSIDIARIES OF ABBOTT LABORATORIES ? The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2021. |
|
| February 19, 2021 |
? Exhibit 10.57 ? ABBOTT LABORATORIES PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT On ?GrantDate? (the ?Grant Date?), Abbott Laboratories hereby grants to ?First Name? ?MI? ?Last Name? (the ?Employee?) a Performance Restricted Stock Unit Award (the ?Award?) of ?NoShares12345? restricted stock units (the ?Units?). The Award is granted under the Program and is subject to the provisions of the Program |
|
| February 19, 2021 |
Common Shares, Without Par Value ABT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 19, 2021 |
By-Laws of Abbott Laboratories, as amended and restated, effective April 23, 2021. Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 23, 2021 BY-LAWS OF ABBOTT LABORATORIES ARTICLE I OFFICES The principal office of the Corporation in the State of Illinois shall be located at the intersection of State Routes 43 and 137 in the County of Lake. The Corpora |
